Intismarin's three expansion vectors beyond melanoma
The guest laid out three strategic vectors for expanding Intismarin's application: combining with Keytruda in cancers where it works, using it as monotherapy in early-stage cancers, and testing it in cancers where checkpoint inhibitors fail.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.